

Lamzede® (velmanase alfa-tycv) (Intravenous)

Document Number: OHSU HEALTHSERVICES-0696

Last Review Date: 04/01/2026

Date of Origin: 03/02/2023

Dates Reviewed: 03/2023, 03/2024, 04/2025, 04/2026

I. Length of Authorization

- Initial: Prior authorization validity will be provided initially for 12 months (365 days).
- Renewal: Prior authorization validity may be renewed every 12 months (365 days) thereafter.

II. Dosing Limits

Max Units (per dose and over time) [HCPCS Unit]:

- 440 billable units every 28 days

III. Initial Approval Criteria ¹

Prior authorization validity is provided in the following conditions:

- Member is at least 3 years of age; **AND**
- Documented baseline serum oligosaccharides; **AND**
- Documented baseline age-appropriate values** for one or more of the following have been obtained: 6-minute walk test (6-MWT), 3-minute stair climb test (3-MSCT), pulmonary function tests (e.g., forced vital capacity [FVC]), motor function (i.e., Bruininks-Oseretsky Test of Motor Proficiency [BOT-2]), etc.; **AND**
- Females of reproductive potential have a confirmed negative pregnancy test prior to initiating treatment; **AND**

****NOTE:** For very young members in which FVC or 6-MWT are not suitable for measuring, requests will be reviewed on a case-by-case basis.

Universal Criteria ^{1,3}

- Therapy is used to treat non-central nervous system manifestations of alpha mannosidosis (i.e., skeletal abnormalities, myopathy, motor function disturbances, immunodeficiency, etc.); **AND**

Alpha Mannosidosis † Φ ¹⁻³

- Member has a definitive diagnosis of alpha mannosidosis as confirmed by ONE of the following:

- Identification of deficient acid alpha-mannosidase enzyme activity in peripheral blood leukocytes or other nucleated cells such as fibroblasts of <11% of normal activity; **OR**
- Identification of biallelic pathogenic (or likely pathogenic) variants in *MAN2B1* by molecular genetic testing

† FDA Approved Indication(s); ‡ Compendia Recommended Indication(s); Ⓢ Orphan Drug

IV. Renewal Criteria ¹⁻³

Prior authorization validity may be renewed based on the following criteria:

- Member continues to meet the universal and other indication-specific relevant criteria such as concomitant therapy requirements (not including prerequisite therapy), performance status, etc. identified in section III; **AND**
- Absence of unacceptable toxicity from the drug. Examples of unacceptable toxicity include: hypersensitivity reactions including anaphylaxis, infusion-associated reactions, etc.; **AND**
- Member has demonstrated a beneficial response to therapy or stabilization of disease compared to pretreatment age-appropriate baseline values in one or more of the following:
 - Stability or improvement in serum oligosaccharide concentration
 - Stability or improvement in 6-minute walking test (6-MWT)
 - Stability or improvement in 3-minute stair climbing test (3-MSCT)
 - Stability or improvement in forced vital capacity (FVC) (% predicted)
 - Stabilization or slowing in the rate of disease progression or clinical decline

V. Dosage/Administration ¹

Indication	Dose
Alpha-mannosidosis	1 mg/kg (actual body weight) administered once every week as an intravenous infusion

VI. Billing Code/Availability Information

HCPCS Code:

- J0217 – Injection, velmanase alfa-tycv, 1 mg; 1 billable unit = 1 mg

NDC:

- Lamzede 10 mg as a lyophilized powder in a single-dose vial for reconstitution: 10122-0180-xx

VII. References

1. Lamzede [package insert]. Cary, NC; Chiesi USA, Inc.; February 2023. Accessed February 2026.

2. Borgwardt L, Guffon N, Amraoui Y, et al. Efficacy and safety of Velmanase alfa in the treatment of patients with alpha-mannosidosis: results from the core and extension phase analysis of a phase III multicentre, double-blind, randomised, placebo-controlled trial. *J Inher Metab Dis*. 2018 Nov;41(6):1215-1223. doi: 10.1007/s10545-018-0185-0. Epub 2018 May 30.
3. Ficicioglu C, Stepien KM. Alpha-Mannosidosis. Initial Posting: October 11, 2001; Last Update: June 13, 2024. In: Adam MP, Bick S, Mirzaa GM, et al, editors. *GeneReviews*® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2026. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK1396/>. Accessed on February 25, 2026.

Appendix A – Non-Quantitative Treatment Limitations (NQTL) Factor Checklist

Non-quantitative treatment limitations (NQTLs) refer to the methods, guidelines, standards of evidence, or other conditions that can restrict how long or to what extent benefits are provided under a health plan. These may include things like utilization review or prior authorization. The utilization management NQTL applies comparably, and not more stringently, to mental health/substance use disorder (MH/SUD) Medical Benefit Prescription Drugs and medical/surgical (M/S) Medical Benefit Prescription Drugs. The table below lists the factors that were considered in designing and applying prior authorization to this drug/drug group, and a summary of the conclusions that Prime's assessment led to for each.

Factor	Conclusion
Indication	Yes: Consider for PA
Safety and efficacy	Yes: Consider for PA
Potential for misuse/abuse	No: PA not a priority
Cost of drug	Yes: Consider for PA

Appendix 1 – Covered Diagnosis Codes

ICD-10	ICD-10 Description
E77.1	Defects in glycoprotein degradation

Appendix 2 – Centers for Medicare and Medicaid Services (CMS)

The preceding information is intended for non-Medicare coverage determinations. Medicare coverage for outpatient (Part B) drugs is outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals. In addition, National Coverage Determinations (NCDs) and/or Local Coverage Determinations (LCDs) may exist and compliance with these policies is required where applicable. Local Coverage Articles (LCAs) may also exist for claims payment purposes or to clarify benefit eligibility under Part B for drugs which may be self-administered. The following link may be used to search for NCD, LCD, or LCA documents: <https://www.cms.gov/medicare-coverage-database/search.aspx>. Additional indications, including any preceding information, may be applied at the discretion of the health plan.

Medicare Part B Covered Diagnosis Codes (applicable to existing NCD/LCD/LCA): N/A

Medicare Part B Administrative Contractor (MAC) Jurisdictions		
Jurisdiction	Applicable State/US Territory	Contractor
E (1)	CA, HI, NV, AS, GU, CNMI	Noridian Healthcare Solutions, LLC
F (2 & 3)	AK, WA, OR, ID, ND, SD, MT, WY, UT, AZ	Noridian Healthcare Solutions, LLC
5	KS, NE, IA, MO	Wisconsin Physicians Service Insurance Corp (WPS)
6	MN, WI, IL	National Government Services, Inc. (NGS)
H (4 & 7)	LA, AR, MS, TX, OK, CO, NM	Novitas Solutions, Inc.
8	MI, IN	Wisconsin Physicians Service Insurance Corp (WPS)
N (9)	FL, PR, VI	First Coast Service Options, Inc.
J (10)	TN, GA, AL	Palmetto GBA
M (11)	NC, SC, WV, VA (excluding below)	Palmetto GBA
L (12)	DE, MD, PA, NJ, DC (includes Arlington & Fairfax counties and the city of Alexandria in VA)	Novitas Solutions, Inc.
K (13 & 14)	NY, CT, MA, RI, VT, ME, NH	National Government Services, Inc. (NGS)
15	KY, OH	CGS Administrators, LLC